Inhibitors of PCSK9 enzyme as a drug for hypercholesterolemia

Abstract

New class of drugs, fully humanized monoclonal antibodies, evolocumab and alirocumab, work as PCSK9 inhibitors. Evolocumab and alirocumab bind free plasma PCSK9 and lead to its degradation, as a result, less free PCSK9 is available in the plasma to bind to LDL-R which help the liver to remove more LDL-C from the circulation, which lower LDL-C plasma levels.